Olema Pharmaceuticals, Inc.
REGIMENS OF ESTROGEN RECEPTOR ANTAGONISTS

Last updated:

Abstract:

Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer. In some embodiments, estrogen receptor antagonists provided herein are tetrahydro pyrido[3,4-b] indole compounds. In some embodiments, provided antagonists are complete estrogen receptor antagonists.

Status:
Application
Type:

Utility

Filling date:

6 Jul 2020

Issue date:

25 Aug 2022